Myeloma Made Simple: Bispecific Antibody Targets Made Simple | Myeloma Targeting with Bispecifics

Know Your Myeloma Immunotherapy: Bispecific Antibodies with Dr. Cesar RodriguezПодробнее

Bispecific Antibodies in Multiple Myeloma | Dana-Farber Cancer InstituteПодробнее

Alfred Garfall, MD and Bea Razzo, MD on Bispecific Antibodies in Multiple MyelomaПодробнее

The importance of BCMA-targeting ADCs and bispecific antibodies in R/R multiple myelomaПодробнее

The safety and efficacy of zilovertamab vedotin in R/R MCL post-BTKiПодробнее

Targeting of Myeloma Disease Progression and Bispecific Antibody AdvantagesПодробнее

What should myeloma patients know about bispecific antibodies?Подробнее

Myeloma Made Simple: Bispecific Antibodies Made Simple | Bispecific Antibodies for Myeloma TreatmentПодробнее

Bispecific Antibodies in MyelomaПодробнее

Targeting BCMA for R/R myelomaПодробнее

Bispecific T-cell engagers in the treatment of myelomaПодробнее

FAQs on BMCA-Targeted Bispecific Antibodies in Multiple MyelomaПодробнее

Targeting BCMA with bispecific antibodies in R/R myelomaПодробнее

SLAMF7 as a target for multiple myelomaПодробнее

Bispecifics, Bispecifics, BispecificsПодробнее

Updates in immunotherapy for multiple myeloma: BiTEs & novel targetsПодробнее

How can BCMA be used as a target for mutiple myeloma treatment?Подробнее

An "Off-the-Shelf" Approach for Myeloma Care: BCMA AntibodiesПодробнее

CD229 as a potential therapeutic target for multiple myelomaПодробнее